GlaxoSmithKline (Spain)-ko ikertzaileekin lankidetzan egindako argitalpenak (13)

2019

  1. Budget impact analysis of subcutaneous belimumab in patients with systemic lupus erythematosus in Spain

    ClinicoEconomics and Outcomes Research, Vol. 11, pp. 757-765

2016

  1. Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic copd spanish patients

    International Journal of COPD, Vol. 11, pp. 123-132

2015

  1. Validation of a Spanish version of the childhood asthma control test (Sc-ACT) for use in Spain

    Anales de Pediatria, Vol. 83, Núm. 2, pp. 94-103

2011

  1. Pharmacokinetic/pharmacodynamic evaluation of amoxicillin, amoxicillin/clavulanate and ceftriaxone in the treatment of paediatric acute otitis media in Spain

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 29, Núm. 3, pp. 167-173

2010

  1. Geographical variations in the prevalence of COPD in Spain: Relationship to smoking, death rates and other determining factors

    Archivos de Bronconeumologia, Vol. 46, Núm. 10, pp. 522-530

  2. Recent trends in COPD prevalence in Spain: A repeated cross-sectional survey 1997-2007

    European Respiratory Journal, Vol. 36, Núm. 4, pp. 758-765

2009

  1. Impact of acute otitis media pathogen shifts on the clinical efficacy of several antibiotics: A therapeutic outcomes model

    Journal of Chemotherapy, Vol. 21, Núm. 4, pp. 408-413

2007

  1. Sensitivity to change, discriminative performance, and cutoff criteria to define remission for embedded short scales of the Hamilton depression rating scale (HAMD)

    Journal of Affective Disorders, Vol. 102, Núm. 1-3, pp. 93-99

  2. The sufficiency of the HAM-D6 as an outcome instrument in the acute therapy of antidepressants in the outpatient setting

    International Journal of Psychiatry in Clinical Practice, Vol. 11, Núm. 2, pp. 146-150

2005

  1. Evaluation of antimicrobial treatments in children with acute otitis media in Spain: A pharmacokinetic-pharmacodynamic (PK/PD) approach

    Journal of Chemotherapy, Vol. 17, Núm. 6, pp. 628-635

  2. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point

    International Journal of Antimicrobial Agents, Vol. 25, Núm. 2, pp. 163-167

2003

  1. Evaluación psicométrica comparativa de las versiones en español de 6, 17 y 21 ítems de la Escala de valoración de Hamilton para la evaluación de la depresión

    Medicina Clinica, Vol. 120, Núm. 18, pp. 693-700

  2. Validación de las versiones en español de la Clinical Anxiety Scale y del Physician Questionnaire para la evaluación de los trastornos de ansiedad

    Medicina Clinica, Vol. 121, Núm. 10, pp. 367-374